Opinion|Podcasts|November 7, 2023

Expert Guidance on Managing Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in an Outpatient Setting

George Sakoulas, MD, provides key insights on the management of soft tissue infections including the role of single-dose agents and treating patients in an outpatient setting.

0:00 Overview of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

2:21 Current Therapies and Treatment Approaches for ABSSSI

7:58 Antimicrobial Stewardship for ABSSSI Single-Dose Agents

10:29 Key Takeaways on Managing ABSSSI

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Related to this article

October 29th, 2026

A Closer Look at IDSA/ESCMID 2026 Consensus Statements 6 and 7 on Staphylococcus aureus Bacteremia

IDSA and ESCMID released 7 consensus statements to assist in managing individuals with Staphylococcus aureus Bacteremia (SAB). This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline.

November 1st, 2026

Nearly 30% of US Adults Report Misrepresenting Symptoms to Get Antibiotics

In a national survey of 959 US adults, 27.9% said they had exaggerated or made up symptoms to obtain antibiotics, most often cold-like symptoms, with implications for outpatient stewardship.

October 30th, 2026

Thinking Outside the IV: Implementation of a COpAT Program for Patients With Bone and Joint Infections

An APP-driven complex outpatient antimicrobial therapy (COpAT) program for patients with bone and joint infections cut mean time to post-discharge follow-up from 20.1 to 9.7 days but did not significantly reduce 30-day readmissions or emergency department visits.

Alisse Hannaford, MD (Image Credit: Mass General)

October 24th, 2026

Early Antibiotic Stop in Neutropenic Fever Did Not Raise Severe Events

Stopping empiric antibiotics early nearly tripled antibiotic-free days in neutropenic fever, and 5-day oseltamivir prophylaxis matched 10 days in hospital exposures.

October 20th, 2026

Maternal Vaccination Shown to Protect Against K Pneumoniae Neonatal Sepsis

The first animal model of neonatal sepsis to evaluate protection by maternal vaccination evidences transfer of immunity against virulent, often antibiotic-resistant Klebseilla pneumoniae.

Expert Guidance on Managing Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in an Outpatient Setting

Related to this article

Trending on Contagion Live

Washington State Reports First US Avian Influenza Death of 2026

Nearly 30% of US Adults Report Misrepresenting Symptoms to Get Antibiotics

Cefiderocol Activity Improves in Physiologic Media, Synergizes With LL-37

FDA Approves Voceryq, First Plasmid DNA Immunotherapy for Recurrent Respiratory Papillomatosis

Cabotegravir Plus Rilpivirine Holds Up in 5 Years of Real-World Data